learn HMI-115
much-hyped research compound targeting prolactin receptor in scalp
Search
forLearn
5 / 801 resultslearn ORPL
learn HT-B
learn RootBioTec HW
learn Overview
Research
5 / 1000+ results
research The ProScope HR: A promising diagnostic tool
The ProScope HR is an effective, user-friendly, and affordable tool for diagnosing hair loss.
research Androgens and the Menopause
Testosterone replacement may help postmenopausal women with sexual function and bone density, but suitable treatments are limited.
research Importance of vascular patterns in the dermoscopy recognition of cutaneous tumors
Vascular patterns in dermoscopy help tell apart malignant and benign skin tumors.
research The evaluation of online tools in the recruitment of dermatology patients for a research study
Online tools are effective and cost-efficient for recruiting dermatology research participants, especially among younger people.
research Digital measurement of melasma: Towards eliminating subjectivity from treatment evaluation
The digital system for measuring melasma shows promise but needs more development for better accuracy and automation.
Community Join
5 / 1000+ resultscommunity What's going on with hmi115? The Phase 2 was concluded Nov2024 but no news
Hmi115, a prolactin receptor blocker, showed promise for hair growth, but results from Phase 2 trials have not been published. ABS-201, an AI-based analog, is expected to begin trials in December 2025, while commercialization of treatments like PP-405 is anticipated around 2027.
community Hope Medicine's HMI-115 could be out in 2027 per Company Founder
Hope Medicine's HMI-115 is expected to be released in 2027, with phase 3 trials currently recruiting. Concerns include the safety of targeting prolactin and the potential cost of the treatment.
community HLT Megathread on HMI-115 (key takeaways in comments)
HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.
community HMI-115 start AGA phase 2 trial volunteer in China. The eligible volunteer should be age between 18 to 65, Norwood 3 vertex , 4 and 5. And agree to prevent pregnancy. The trial is leaded by the doctor in Beijing hospital.
The post discusses a phase 2 trial for HMI-115, a hair loss treatment, in China, specifically seeking volunteers aged 18-65 with Norwood 3 vertex, 4, and 5 hair loss. The conversation includes questions about the specific recruitment criteria and how to volunteer.
community HMI-115 Australian Phase 1 Trial completed?
The post discusses the completion of the HMI-115 Australian Phase 1 Trial for hair loss treatment. The user speculates about the potential early release of the trial results.